In addition, the statistical difference between patients with ER + /HER2- breast cancer with a higher predicted ER activity score (but not those with a lower predicted ER activity score) and patients with TNBC confirmed that our model is predictive of endocrine therapy response in those with ER + /HER2- disease but not in those without ESR1 expression. The gene discussed is ERBB2; the disease is breast cancer.